• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)

EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)

by Elena Iemma | Dec 15, 2020 | News

PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...
Press Release: EpiVax Announces Licensing of Immunogenicity Screening Toolkit, ISPRI, to AbCellera

Press Release: EpiVax Announces Licensing of Immunogenicity Screening Toolkit, ISPRI, to AbCellera

by Elena Iemma | Jun 8, 2020 | News

PROVIDENCE, RI, June 8, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) a Rhode Island-based  company and recognized leader in the field in the field of immunogenicity assessment today announced it has licensed its advanced in silico toolkit for biologics...
Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

by Sarah Moniz | Dec 27, 2019 | News

Providence, R.I., December 23, 2019 – EpiVax (“EpiVax, Inc.”) continues its record-breaking performance and growth in personnel in 2019 while identifying new milestones to aspire to in 2020. The Business Development team closed 15% more contracts over 2018 and...
Press Release: EpiVax Announces Record Year for Growth in 2019 and Sets New Milestones for 2020

Press Release: Chugai Renews License to EpiVax’s ISPRI In Silico Toolkit for Immunogenicity Assessment

by Elena Iemma | Oct 23, 2019 | News

Announced today, Chugai Pharmaceutical Co., Ltd. (“Chugai”), a member of the Roche Group, will extend the company’s licensed access to the Immunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc....
EpiVax Opens New Headquarters and Celebrates 20 Years of Fearless Science

EpiVax Opens New Headquarters and Celebrates 20 Years of Fearless Science

by Sarah Moniz | Jun 11, 2018 | News

PROVIDENCE, R.I., June 11, 2018 — EpiVax announces their move to a new headquarters at 188 Valley Street, in the “Rising Sun” complex, a former wool mill in the Olneyville section of Providence, Rhode Island. The privately held bioinformatics company is also...
Next Entries »

Recent Posts

  • EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
  • EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 
  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}